AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$BLLN

Atay Oguzhan sold $1.0M of BLLN

Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $120.64 ($1.01M total) on 2026-09-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 1, 2026, 12:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The market may view the CEO's total divestiture as a lack of confidence, prompting short‑term selling pressure.

02

Market read

Insider sell of the CEO in a micro‑cap can trigger short‑term price decline; traders should monitor volume and any subsequent news.

03

What to watch

Potential tax planning or personal liquidity needs may have driven the sale, not company fundamentals.

Relevance 5/10Novelty 5/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales, but a complete exit by the CEO is noteworthy.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CEO Atay Oguzhan sold 8,333 shares for $1.0M via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

likely downward pressure as the market prices the insider divestiture

Evidence & confidence

A chief executive exiting his position entirely is a material insider event, especially for a micro‑cap, and markets typically react negatively.

Market effects

Sector

Minimal; the sale is company‑specific and does not affect the broader sector.

Regional

None; the filing is U.S. SEC‑based and pertains only to BillionToOne.

Global

Low; limited to investors in the micro‑cap stock.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not necessarily a negative signal.

Key entities

  • company
    BillionToOne, Inc.

    Micro‑cap biotech listed on NASDAQ under ticker BLLN.

  • person
    Atay Oguzhan

    Chairman and CEO of BillionToOne, executing a 10b5‑1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLLN insider trading history →

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min